Effect of pulmonary rehabilitation programs including lower limb endurance training on dyspnea in stable COPD: a systematic review and meta-analysis
Y Higashimoto, M Ando, A Sano, S Saeki… - Respiratory …, 2020 - Elsevier
Pulmonary rehabilitation (PR) is recommended as an effective treatment for patients with
chronic obstructive pulmonary disease (COPD). Previous meta-analyses showed that PR …
chronic obstructive pulmonary disease (COPD). Previous meta-analyses showed that PR …
Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer
Y Tomita, T Ikeda, S Sakata, K Saruwatari, R Sato… - Cancer immunology …, 2020 - AACR
Gut dysbiosis caused by antibiotics impairs response to immune checkpoint blockade (ICB).
Gut microbiota is becoming an attractive therapeutic target for cancer. The Clostridium …
Gut microbiota is becoming an attractive therapeutic target for cancer. The Clostridium …
Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors
Y Tomita, Y Goto, S Sakata, K Imamura… - …, 2022 - Taylor & Francis
Oral microbiota is associated with human diseases including cancer. Emerging evidence
suggests that proton pump inhibitors (PPIs), which allow the oral microbiome to translocate …
suggests that proton pump inhibitors (PPIs), which allow the oral microbiome to translocate …
Decrease in hemoglobin level predicts increased risk for severe respiratory failure in COVID-19 patients with pneumonia
M Anai, K Akaike, H Iwagoe, T Akasaka, T Higuchi… - Respiratory …, 2021 - Elsevier
Abstract Background In December 2019, the coronavirus disease (COVID-19), caused by
the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), emerged in Wuhan …
the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), emerged in Wuhan …
[HTML][HTML] Disorder of coagulation-fibrinolysis system: an emerging toxicity of anti-PD-1/PD-L1 monoclonal antibodies
R Sato, K Imamura, S Sakata, T Ikeda, Y Horio… - Journal of clinical …, 2019 - mdpi.com
A disruption of immune checkpoints leads to imbalances in immune homeostasis, resulting
in immune-related adverse events. Recent case studies have suggested the association …
in immune-related adverse events. Recent case studies have suggested the association …
[HTML][HTML] Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer …
R Kato, H Hayashi, Y Chiba, E Miyawaki… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Studies have suggested that chemotherapy after immune checkpoint inhibitors
may confer an improved response for non–small cell lung cancer (NSCLC). However …
may confer an improved response for non–small cell lung cancer (NSCLC). However …
TGFβ signaling activated by cancer-associated fibroblasts determines the histological signature of lung adenocarcinoma
R Sato, K Imamura, T Semba, Y Tomita, S Saeki… - Cancer Research, 2021 - AACR
Invasive lung adenocarcinoma (LADC) can be classified histologically as lepidic, acinar,
papillary, micropapillary, or solid. Most LADC tumors manifest several of these histological …
papillary, micropapillary, or solid. Most LADC tumors manifest several of these histological …
Combination bezafibrate and nivolumab treatment of patients with advanced non–small cell lung cancer
K Tanaka, K Chamoto, S Saeki, R Hatae… - Science Translational …, 2022 - science.org
Despite the success of cancer immunotherapies such as programmed cell death–1 (PD-1)
and PD-1 ligand 1 (PD-L1) inhibitors, patients often develop resistance. New combination …
and PD-1 ligand 1 (PD-L1) inhibitors, patients often develop resistance. New combination …
[HTML][HTML] Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small …
S Hamada, H Ichiyasu, T Ikeda, M Inaba… - BMC pulmonary …, 2019 - Springer
Background Acute exacerbation of interstitial lung disease (AE-ILD) is the most serious
complication in lung cancer patients with pre-existing ILD receiving chemotherapy. The role …
complication in lung cancer patients with pre-existing ILD receiving chemotherapy. The role …
Trousseau's syndrome triggered by an immune checkpoint blockade in a non-small cell lung cancer patient.
Y Horio, K Takamatsu, D Tamanoi, R Sato… - European Journal of …, 2018 - europepmc.org
PD-1 blockade therapy activates T cells by blocking the interaction between PD-1 and PD-
L1 and promotes IFN-γ and Th1 cytokine production. In turn, IFN-γ and Th1 cytokines …
L1 and promotes IFN-γ and Th1 cytokine production. In turn, IFN-γ and Th1 cytokines …